TAE-226 is an inhibitor of focal adhesion kinase (FAK) that exhibits anti-angiogenic and anticancer activities. In vitro, this compound inhibits angiogenesis, decreases the viability of cancer cells, and suppresses generation of thromboxane A2 (TxA2).
| Cas No. | 761437-28-9 |
|---|---|
| Purity | ≥98% |
| Formula | C23H25ClN6O3 |
| Formula Wt. | 468.94 |
| IUPAC Name | 2-[(5-Chloro-2-{[2-methoxy-4-(4-morpholinyl)phenyl]amino}-4-pyrimidinyl)amino]-N-methylbenzamide |
| Synonym | NVP-TAE226 |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | T0216 Info Sheet PDF |
|---|
Dao P, Jarray R, Le Coq J, et al. Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4552-6. PMID: 23845217.
Golubovskaya VM, Ho B, Zheng M, et al. Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities. Anticancer Agents Med Chem. 2013 May;13(4):546-54. PMID: 22292772.
Bhavaraju K, Lakhani PR, Dorsam RT, et al. G(12/13) signaling pathways substitute for integrin αIIbβ3-signaling for thromboxane generation in platelets. PLoS One. 2011 Feb 10;6(2):e16586. PMID: 21347357.
